Showing 8401-8410 of 8877 results for "".
- OHSU Releases Mole Mapper App to Track Potential Skin Cancershttps://practicaldermatology.com/news/ohsu-releases-mole-mapper-app-to-track-potential-skin-cancers/2458843/Oregon Health & Science University released an iPhone app it says is designed to advance melanoma research by giving users the ability to accurately measure and monitor moles, and contribute photos of how their potential trouble spots evolve over time. Called Mole Mapper, the app is free to d
- RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109https://practicaldermatology.com/news/rxi-pharmaceuticals-announces-positive-interim-results-in-phase-2a-dermatology-program-with-rxi-109/2458844/RXi Pharmaceuticals Corporation shared results from a blinded panel and an Investigator review showing that incision sites treated with RXI-109 after scar revision surgery achieved better scores as compared to control incision sites in the same subjects, three months post scar revision surgery.</
- Fibrocell and Intrexon: Highlights of Pre-Clinical Data for Potential First-in-Class Treatment for Recessive Dystrophic Epidermolysis Bullosahttps://practicaldermatology.com/news/fibrocell-and-intrexon-highlights-of-pre-clinical-data-for-potential-first-in-class-treatment-for-recessive-dystrophic-epidermolysis-bullosa/2458847/Fibrocell Science, Inc., and Intrexon Corporation are highlighting a poster entitled “Pre-Clinical Development of a Genetically-Modified Human Dermal Fibroblast (FCX-007) for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)” being presented at the American Society of
- FDA Approves Juvederm® Ultra XC for Use in Lipshttps://practicaldermatology.com/news/fda-approves-juvederm-ultra-xc-for-use-in-lips/2458860/Allergan has received FDA approval to market Juvederm® Ultra XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. It is the only dermal filler that has proven results lasting up to one year for lip augmentation
- Revance Therapeutics Initiates Phase 3 Clinical Trial of Botulinum Toxin Type A Topical Gel for Crow's Feethttps://practicaldermatology.com/news/revance-therapeutics-initiates-phase-3-clinical-trial-of-botulinum-toxin-type-a-topical-gel-for-crows-feet/2458857/Revance Therapeutics, Inc. has commenced dosing patients in the Phase 3 pivotal study to evaluate the safety and efficacy of its RT001 investigational topical drug product candidate for the treatment of lateral canthal lines, or crow’s feet. The Phase 3 trial will evaluate the safety and ef
- Curology Launches Online Service For Customized Prescription Skincarehttps://practicaldermatology.com/news/curology-launches-online-service-for-customized-prescription-skincare/2458862/Curology launched a first-of-its-kind online service that offers customized prescription creams for acne and anti-aging. Founded by dermatologist Dr. David Lortscher, Curology partners patients with licensed healthcare professionals and custom-formulates medications at its laboratory in San Diego
- Report: Prescription Dermatological Drug Market Exceeds 21 Billion Dollarshttps://practicaldermatology.com/news/report-prescription-dermatological-drug-market-exceeds-21-billion-dollars/2458870/The worldwide market for prescription dermatological drugs exceeded $21 billion last year, according to a report from Kalorama Information. The market research firm said field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options
- Report Predicts Growth in Global Dermatology Diagnostic Devices Market 2015-2019https://practicaldermatology.com/news/report-predicts-growth-in-global-dermatology-diagnostic-devices-market-2015-2019/2458869/A recently published report, Global Dermatology Diagnostic Devices Market 2015-2019, which was prepared based on an in-depth market analysis with inputs from industry experts
- FDA Issues Consumer Update about Injectable Skin Lightening Productshttps://practicaldermatology.com/news/fda-issues-consumer-update-about-injectable-skin-lightening-products/2458879/A consumer update from the FDA warns that injectable skin lightening products are unapproved, untested drugs that could potentially cause harm. The FDA adds that it has not approved any injectable drugs for skin whitening or lightening. “These products pose a potentially significant
- FDA Warns of Severe Adverse Events with Application of Picato (ingenol mebutate) Gel; Requires Label Changeshttps://practicaldermatology.com/news/fda-warns-of-severe-adverse-events-with-application-of-picato-ingenol-mebutate-gel-requires-label-changes/2458878/The FDA released a Drug Safety Communication to warn about reports of severe allergic reactions and herpes zoster (shingles) associated with the use of Picato gel (ingenol mebutate), which is approved to treat actinic keratosis. The FDA said it also received reports of cases involving sev